A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918

Vinay K. Malviya, P. Y. Liu, David A. Goldberg, Alexander Hantel, Robert V. O'Toole, Ralph W. Roach, Marcel E. Conrad, David S Alberts

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A phase II trial of the new anthrapyrazole piroxantrone was carried out by the Southwest Oncology Group in patients with advanced metastatic or recurrent endometrial cancer. A two-stage statistical design targeted accrual of 20 eligible patients. The starting dose of piroxantrone was 150 mg/m2 in patients without prior radiation therapy (RT) and 120 mg/m2 in patients with prior RT. There were 15 eligible patients, six of whom had received prior hormonal therapy while nine patients had not received prior hormonal therapy. Eight patients had received prior RT while seven patients had not received any prior RT. One to seven cycles of piroxantrone were administered. Dose escalation was feasible in four patients. No grade 5 toxicity was experienced by any patients. Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression. Grade 3 non-hematologic toxicities were nausea, fatigue and SGOT elevation. There was one partial response for a response rate of 7% (95% CI 0.2-32%) and median survival was 11 months (95% CI 3-13 months). The study was prematurely terminated due to lack of patient accrual.

Original languageEnglish (US)
Pages (from-to)527-530
Number of pages4
JournalAnti-Cancer Drugs
Volume7
Issue number5
StatePublished - 1996

Fingerprint

piroxantrone
Endometrial Neoplasms
Radiotherapy
Agranulocytosis

Keywords

  • advanced endometrial cancer
  • piroxantrone
  • recurrent endometrial cancer

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Malviya, V. K., Liu, P. Y., Goldberg, D. A., Hantel, A., O'Toole, R. V., Roach, R. W., ... Alberts, D. S. (1996). A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918. Anti-Cancer Drugs, 7(5), 527-530.

A phase II trial of piroxantrone in endometrial cancer : Southwest Oncology Group Study 8918. / Malviya, Vinay K.; Liu, P. Y.; Goldberg, David A.; Hantel, Alexander; O'Toole, Robert V.; Roach, Ralph W.; Conrad, Marcel E.; Alberts, David S.

In: Anti-Cancer Drugs, Vol. 7, No. 5, 1996, p. 527-530.

Research output: Contribution to journalArticle

Malviya, VK, Liu, PY, Goldberg, DA, Hantel, A, O'Toole, RV, Roach, RW, Conrad, ME & Alberts, DS 1996, 'A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918', Anti-Cancer Drugs, vol. 7, no. 5, pp. 527-530.
Malviya VK, Liu PY, Goldberg DA, Hantel A, O'Toole RV, Roach RW et al. A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918. Anti-Cancer Drugs. 1996;7(5):527-530.
Malviya, Vinay K. ; Liu, P. Y. ; Goldberg, David A. ; Hantel, Alexander ; O'Toole, Robert V. ; Roach, Ralph W. ; Conrad, Marcel E. ; Alberts, David S. / A phase II trial of piroxantrone in endometrial cancer : Southwest Oncology Group Study 8918. In: Anti-Cancer Drugs. 1996 ; Vol. 7, No. 5. pp. 527-530.
@article{fd486f8d8bdc4041bbd7235f3c9054fd,
title = "A phase II trial of piroxantrone in endometrial cancer: Southwest Oncology Group Study 8918",
abstract = "A phase II trial of the new anthrapyrazole piroxantrone was carried out by the Southwest Oncology Group in patients with advanced metastatic or recurrent endometrial cancer. A two-stage statistical design targeted accrual of 20 eligible patients. The starting dose of piroxantrone was 150 mg/m2 in patients without prior radiation therapy (RT) and 120 mg/m2 in patients with prior RT. There were 15 eligible patients, six of whom had received prior hormonal therapy while nine patients had not received prior hormonal therapy. Eight patients had received prior RT while seven patients had not received any prior RT. One to seven cycles of piroxantrone were administered. Dose escalation was feasible in four patients. No grade 5 toxicity was experienced by any patients. Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression. Grade 3 non-hematologic toxicities were nausea, fatigue and SGOT elevation. There was one partial response for a response rate of 7{\%} (95{\%} CI 0.2-32{\%}) and median survival was 11 months (95{\%} CI 3-13 months). The study was prematurely terminated due to lack of patient accrual.",
keywords = "advanced endometrial cancer, piroxantrone, recurrent endometrial cancer",
author = "Malviya, {Vinay K.} and Liu, {P. Y.} and Goldberg, {David A.} and Alexander Hantel and O'Toole, {Robert V.} and Roach, {Ralph W.} and Conrad, {Marcel E.} and Alberts, {David S}",
year = "1996",
language = "English (US)",
volume = "7",
pages = "527--530",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A phase II trial of piroxantrone in endometrial cancer

T2 - Southwest Oncology Group Study 8918

AU - Malviya, Vinay K.

AU - Liu, P. Y.

AU - Goldberg, David A.

AU - Hantel, Alexander

AU - O'Toole, Robert V.

AU - Roach, Ralph W.

AU - Conrad, Marcel E.

AU - Alberts, David S

PY - 1996

Y1 - 1996

N2 - A phase II trial of the new anthrapyrazole piroxantrone was carried out by the Southwest Oncology Group in patients with advanced metastatic or recurrent endometrial cancer. A two-stage statistical design targeted accrual of 20 eligible patients. The starting dose of piroxantrone was 150 mg/m2 in patients without prior radiation therapy (RT) and 120 mg/m2 in patients with prior RT. There were 15 eligible patients, six of whom had received prior hormonal therapy while nine patients had not received prior hormonal therapy. Eight patients had received prior RT while seven patients had not received any prior RT. One to seven cycles of piroxantrone were administered. Dose escalation was feasible in four patients. No grade 5 toxicity was experienced by any patients. Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression. Grade 3 non-hematologic toxicities were nausea, fatigue and SGOT elevation. There was one partial response for a response rate of 7% (95% CI 0.2-32%) and median survival was 11 months (95% CI 3-13 months). The study was prematurely terminated due to lack of patient accrual.

AB - A phase II trial of the new anthrapyrazole piroxantrone was carried out by the Southwest Oncology Group in patients with advanced metastatic or recurrent endometrial cancer. A two-stage statistical design targeted accrual of 20 eligible patients. The starting dose of piroxantrone was 150 mg/m2 in patients without prior radiation therapy (RT) and 120 mg/m2 in patients with prior RT. There were 15 eligible patients, six of whom had received prior hormonal therapy while nine patients had not received prior hormonal therapy. Eight patients had received prior RT while seven patients had not received any prior RT. One to seven cycles of piroxantrone were administered. Dose escalation was feasible in four patients. No grade 5 toxicity was experienced by any patients. Most of the grade 4 (granulocytopenia in one) and grade 3 (leukopenia in three, granulocytopenia in three, anemia in two and thrombocytopenia in one) toxicity was related to myelosuppression. Grade 3 non-hematologic toxicities were nausea, fatigue and SGOT elevation. There was one partial response for a response rate of 7% (95% CI 0.2-32%) and median survival was 11 months (95% CI 3-13 months). The study was prematurely terminated due to lack of patient accrual.

KW - advanced endometrial cancer

KW - piroxantrone

KW - recurrent endometrial cancer

UR - http://www.scopus.com/inward/record.url?scp=0029795170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029795170&partnerID=8YFLogxK

M3 - Article

C2 - 8862719

AN - SCOPUS:0029795170

VL - 7

SP - 527

EP - 530

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -